

**BOARD OF PHARMACY
JOINT COMMITTEE MEETING
DRAFT MINUTES
October 1, 2021
12:30 p.m. ET
Call In Number: (888) 585-9008
Conference Code: 599-196-982(#)**

Participants in this public meeting should be aware that these proceedings are being recorded and that an audio file of the meeting will be posted to the board's website.

I. CALL TO ORDER/ROLL CALL

MEMBERS PRESENT

Jeffrey Mesaros, PharmD, JD, Chair
Jonathan Hickman, PharmD
Jeenu Philip, BPharm
Patty Ghazvini, PharmD, BCGP

STAFF PRESENT

Jessica Sapp, Executive Director
Traci Zeh, Program Administrator

COURT REPORTER

For the Record
150 Mahan Drive, Suite 140
Tallahassee, FL 32308
(850) 222-5491
(850) 224-5316 (Fax)

BOARD COUNSEL

David Flynn, Esq.
Senior Assistant Attorney General
Christopher Dierlam, Esq.
Assistant Attorney General

JOINT COMMITTEE MEMBERS PRESENT

Michael Wasyluk, MD, Board of Medicine
Sandra Schwemmer, DO, Board of Osteopathic Medicine
Michelle R. Mendez, DO, Board of Osteopathic Medicine

Also present on the call was Ed Tellechea, counsel to the Board of Medicine, Paul Vazquez, Executive Director for the Board of Medicine, Donna McNulty, counsel to the Board of Osteopathic Medicine and Kama Monroe, Executive Director for the Board of Osteopathic Medicine.

II. NEW BUSINESS

a. Application for Initial Test and Treat Certification Course

The Board of Pharmacy received an Initial Test and Treat Certification Course Provider Application from Nova Southeastern University College of Pharmacy Section 465.1895(2)(b) requires the application be reviewed and approved by the Board of Pharmacy, in consultation with the Boards of Medicine and Osteopathic Medicine.

64B16-31.035 Test and Treat Certification: Initial Certification Course.

(1) Applicants for Initial Certification Course approval shall submit an application using Form DH5062-MQA (eff. 08/20) "Application for Initial Test and Treat Certification Course" that is hereby incorporated by reference and available at <http://www.flrules.org/Gateway/reference.asp?No=Ref-12228> or <http://floridapharmacy.gov>.

(2) Initial test and treat certification courses shall be a minimum of 20 hours in duration, and shall meet all the following mandatory requirements:

(a) The course may only be offered by a program provider who is accredited by the Accreditation Council for Pharmacy Education (ACPE), a program provider who is accredited to provide educational activities designated for the American Medical Association Physician's Recognition Award Category 1 credit, or a program provider approved by the American Osteopathic Association to offer continuing medical education credits.

(b) The course content and objectives offered by an approved provider shall be developed in conjunction with an individual licensed to practice pharmacy and an individual who is licensed allopathic or osteopathic physician.

(c) The course content shall include all those areas enumerated in Section 465.1895(2)(b), F.S., and shall also cover the following areas:

1. Laws and rules applicable to test and treat certifications; and
2. Writing and entering into a written protocol.

(d) No less than 8 hours of the course shall be offered through a live seminar or a live video teleconference.

(3) A pharmacist who successfully completes a board approved test and treat certification course shall be awarded 20 hours of general continuing education credits.

Dr. Hickman indicated that this is an ACPE accredited provider as well as a former Board Member of the Board of Pharmacy included in the list of faculty members. He indicated all necessary elements were captured in the application and is in favor of accepting the application.

Dr. Schwemmer addressed the Committee and recused herself as she is currently employed as a health care professional at NOVA and believes it would be a conflict of interest to be included in the vote.

Mr. Philip addressed the Committee in favor of approving the application.

Motion: by Mr. Philip to approve the application and present to the Full Board of Pharmacy.

Seconded: by Dr. Ghazvini

Vote: Unanimous

Mr. Philip expressed interest in streamlining the review and approval process of the Test and Treat and Collaborative Practice applications. He suggested sending the applications to one member of the committee of each profession, should it not need additional review it could be placed on the Board of Pharmacy agenda for final approval; however, if additional discussion regarding the application should be warranted, the Committee would call a Joint meeting.

Mr. Flynn addressed the Committee and indicated he would research additional options for approving the applications.

Mr. Tellechea indicated if there is more than one person in the Committee reviewing the applications and making recommendations, that would be a violation of the Sunshine Law.

Mr. Flynn suggested, if the Committee chose to, each profession could have one individual representing their Board; therefore, minimizing time utilized by multiple members from each profession.

Dr. Mendez addressed the Committee opposed to changing the make-up of the Joint Committee at this time, stating it is premature and suggested all Board Counsels review the statutes in order to capture the intent of the legislation.

Dr. Schwemmer addressed the Committee in agreeance with Dr. Mendez.

After discussion, it was determined, the Committee will keep the current format and allow Board Counsels to research the possibility of streamlining the process.

III. ADJOURNMENT

There being no further business the meeting adjourned at 12:50 p.m. ET.